|
Market Closed -
OTC Markets
15:58:17 2023-09-07 EDT
|
5-day change | 1st Jan Change | ||
| 120,000.00 USD | -.--% |
|
-20.00% | -20.00% |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index | CI |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index | CI |
| Market Cap | 51.95M 44.7M 42.06M 38.42M 71.87M 4.9B 72.07M 497M 193M 2.52B 195M 191M 8.11B | P/E 2019 * |
-
| P/E 2020 | - |
|---|---|---|---|---|---|
| Enterprise Value | -99.99M -86.04M -80.95M -73.95M -138M -9.44B -139M -957M -371M -4.84B -375M -367M -15.6B | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
96% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 week | -20.00% | ||
| Current month | -20.00% | ||
| 1 month | -20.00% | ||
| 3 months | -20.00% | ||
| 6 months | -20.00% | ||
| Current year | -20.00% |
| 3 years | 3,000 |  | 399,160 |
| 5 years | 3,000 | | 399,160 |
| 10 years | 3,000 | | 3,719,992 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Hearne
DFI | Director of Finance/CFO | 63 | 2018-11-18 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/1/21 | EcoR1 Capital, LLC
| Buy | Company | 6,073,551 | 15.7794% | |
| 11/22/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 400,000 | 1.0390% | |
| 11/17/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 1,000,000 | 2.5974% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -20.00% | -20.00% | -.--% | 53.25M | |
| -0.88% | -2.15% | +54.71% | +106.31% | 1,024B | |
| -1.15% | +2.68% | +53.97% | +71.50% | 663B | |
| -1.44% | +0.38% | +20.40% | +73.05% | 453B | |
| +0.14% | -0.47% | +29.49% | +38.56% | 352B | |
| -1.33% | +4.72% | +24.69% | +45.55% | 304B | |
| -1.15% | +0.30% | -1.49% | +12.31% | 252B | |
| -1.55% | +1.11% | +56.10% | +70.32% | 236B | |
| -0.88% | +1.15% | -17.09% | -54.39% | 206B | |
| -0.15% | +3.65% | +33.90% | +96.99% | 187B | |
| Average | -0.89% | +0.98% | +23.47% | +46.02% | 367.84B | |
| Weighted average by Cap. | -1.10% | +0.55% | +36.62% | +66.22% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -112M -96.23M -90.53M -82.7M -155M -10.56B -155M -1.07B -415M -5.42B -420M -411M -17.45B | -126M -109M -102M -93.45M -175M -11.93B -175M -1.21B -469M -6.12B -474M -464M -19.72B |
| Net Debt | -178M -154M -144M -132M -247M -16.84B -247M -1.71B -662M -8.64B -670M -655M -27.84B | -152M -131M -123M -112M -210M -14.35B -211M -1.45B -564M -7.36B -571M -558M -23.71B |
Employees
145
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ODTC Stock
Select your edition
All financial news and data tailored to specific country editions
